We expect that the decision aid will support patients in deciding about prostate cancer treatment by decreasing decisional conflict and regret. We also expect and an improvement of treatment satisfaction and health-related quality of life.
ID
Bron
Verkorte titel
Aandoening
Prostate cancer, prostaatkanker
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Decisional conflict (short term),
decisional regret and treatment satisfaction (long term). All measured by questionnaires.
Achtergrond van het onderzoek
At an early stage, prostate cancer patients are often eligible for more than one treatment option, including active surveillance. In terms of long-time survival no treatment option is superior. To choose the most suitable treatment, a patient has to weigh his personal preferences against the risk involved to the cancer and the occurrence of side-effects from treatment. To stimulate shared decision making between a patient and his physician, decision aids (DA's) have proven to be a valuable tool but routine use in clinical practice is lagging behind. For this study an existing prostate cancer treatment DA is adjusted to Dutch context for use at minimal effort and optimal support in clinical consultation. This has resulted in an innovative, web based DA. The aim of this study is to investigate the effectiveness of this tool as well as implementation in clinical practice.
Country of recruitment: The Netherlands
Doel van het onderzoek
We expect that the decision aid will support patients in deciding about prostate cancer treatment by decreasing decisional conflict and regret. We also expect and an improvement of treatment satisfaction and health-related quality of life.
Onderzoeksopzet
T0: Registration; after diagnosis, but before a treatment decision is made (no questionnaire).
T1: After treatment decision making (approximately two weeks after registration)
T2: Follow-up after 6 months
T3: Follow-up after 12 months
Onderzoeksproduct en/of interventie
The control group will receive usual care; information provision and provided decisional support will be given according to the hospital standards.
In addition to usual care, the intervention group will be granted access to an online decision aid, providing patients with structured information on the risks and benefits of the different treatment options and offer value-clarification tasks. A summary is obtained to discuss with their physician during the following consultation.
Publiek
Social and Behavioral Sciences
PO Box 90153
M. Cuypers
Tilburg 5000 LE
The Netherlands
+31 13 466 28 55
M.Cuypers@uvt.nl
Wetenschappelijk
Social and Behavioral Sciences
PO Box 90153
M. Cuypers
Tilburg 5000 LE
The Netherlands
+31 13 466 28 55
M.Cuypers@uvt.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
- Men that are newly diagnosed with early stage prostate cancer;
- Tumour stage T1 or T2;
- Maximum PSA-score of 20;
- Maximum Gleason-score of 7;
- Patients who are eligible for at least two treatment options;
- Patients (in the intervention arm) have to be able to make use of a computer with internet-access in order make use of the web-based decision aid.
- Patients have to be able to read and understand Dutch language.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Patients with advanced cancer;
- If the urologist judges the patient is not in the right condition to participate;
- In the case of a second opinion when the other involved hospital also uses a decision aid from this or an other study.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL4432 |
| NTR-old | NTR4554 |
| Ander register | METC Brabant : NW2014-03 |